Abstract
Gene therapy has come a long way during the past few years to become one of
the most sought after methods to develop a disease treatment. In spite of only
one therapy reaching the markets, the future seems to hold significant
potential in terms of developing such approaches. Gene therapy advancements
have allowed researchers to work with information regarding pathogenesis of
diseases. The discipline heralds a significant potential for the biotechnology
industry over the long term, as the approach moves from research labs to
clinical trials.
According to our new research report, "Global Gene Therapy Market Analysis",
the global gene therapy market is anticipated to grow stupendously in the
coming years. The growth will be largely driven by the increasing interest of
biopharma companies in the segment. The companies will not only look to
develop the therapies for various diseases through in-house research, but also
develop the ones acquired from other sources into full-fledged commercial
forms. The industry is hailing gene therapy as the next frontier of medicine
for its disease-specific approach which hits the target cause of the problem
with utmost efficiency. As a result of this, the therapies currently in the
development stage are able to clear the hurdles of safety and efficacy and are
well on their way to being approved by the regulatory authorities.
Through in-depth and prudent analysis of the developments taking place at the
global level, we have observed that the market is presently dominated by
Oncology, Infectious diseases, and genetic disorder applications. However,
therapeutic applications of gene therapy are extending to new therapy areas
such as acquired diseases, especially the immunodeficiency syndromes. In
addition, smaller companies are likely to become more visible in future as
their products move closer to regulatory approvals.
Further, the US, Europe, Canada, China, and Japan are the major geographical
markets exhibiting healthy growth rates. Our study indicates that the highest
growth rate in the developing countries' gene therapy market is likely to be
observed for the treatment of cancer, followed by infectious diseases like
AIDS, etc.
The report provides extensive information and rational analysis of the global
gene therapy market. Our team of researchers has thoroughly examined current
market trends, industrial developments, and competitive landscapes to enable
clients understand the market structure and its progress in the coming years.
The report also gives an insight into the segment-wise market trends
prevailing at the regional level to provide an overview of developments taking
place in these segments across the world.
Table of Contents
1. Analyst View
2. Research Methodology
3. Gene Therapy - An Introduction
4. Industry Trends
- 4.1 Gene Silencing: Eradicating the Root Cause
- 4.2 Advanced Therapies Combining Gene Therapy and Stem Cell Technology
- 4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
- 4.4 Expanded Use of Viral Vectors
- 4.5 Nanotechnology: Empowering Gene Therapy
5. Industry Overview
- 5.1 Market Size and Growth
- 5.2 By Application
- 5.2.1 Oncology
- 5.2.2 Infectious Diseases
- 5.2.3 Genetic Disorders
- 5.2.4 Acquired Diseases
- 5.3 Key Geographical Markets
- 5.3.1 US
- 5.3.2 Europe
- 5.3.3 Australia
- 5.3.4 Canada
- 5.3.5 Israel
- 5.3.6 Japan
- 5.3.7 China
- 5.3.8 India
- 5.4 Major Drugs
- 5.4.1 Gendicine
- 5.4.2 Oncorine
- 5.4.3 Cerepro
- 5.4.4 Glybera
6. Research & Development
- 6.1 By Stages
- 6.1.1 Phase I & II
- 6.1.2 Phase III
- 6.1.3 Phase IV
- 6.2 By Geography
7. Regulatory Environment
8. Key Players Analysis
- 8.1 Pfizer
- 8.2 GlaxoSmithKline
- 8.3 Genentech
- 8.4 Astrazeneca
- 8.5 Merck KGaA
- 8.6 ImClone LLC
- 8.7 Ark Therapeutics
- 8.8 Celgene Corporation
- 8.9 Shenzhen Si Biono Genetech Co. Ltd
- 8.10 Takeda Pharmaceuticals
List of Figures:
- Figure 3-1: Schematic Diagram of Gene Therapy Technique
- Figure 5-1: Global - Gene Therapy Market (Million US$), 2006 & 2011
List of Tables:
- Table 6-1: Gene Therapy Industry Studies (2011)
- Table 6-2: Gene Therapy Industry Open Studies in Phase III
- Table 6-3: Gene Therapy Industry Open Studies in Phase IV
- Table 6-4: Open Gene Therapy Industry Trials by Country (2011)
- Table 8-1: Global - Major Gene Therapy Companies
